References
- Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S. Aspirin reduces adverse effects of gefitinib. Anticancer Drugs 2006; 17: 423–427
- Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non small cell lung cancer. N Eng J Med 2005; 353: 123–132
- Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Riberiro R, Gerogianni A, et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24: 3831–3837
- Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S. Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance. Clin Appl Thrombosis/Hemostasis 2005; 11: 429–434
- Kanazawa S, Yamaguchi K, Kinoshita Y, Komiyama Y, Muramatsu M, Nomura S. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. J Cancer Res Clin Oncol 2006; 132: 719–725
- Kanazawa S, Muramatsu M, Kinoshita Y, Yamaguchi K, Nomura S. Gefitinib has the potential of activating cell immunity against malignant cells. J Clin Oncol 2005; 23: 3865–3866
- Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Dauillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, et al. Multi institutional randomized phase trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237–2246
- Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, Suga M. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003; 40: 339–342
- Nomura S, Inami N, Ozaki Y, Kagawa H, Fukuhara S. Significance of microparticles in progressive systemic sclerosis with interstitial pneumonia. Platelets 2008; 19: 192–198